My discussion with chatGPT about sene... - Advanced Prostate...

Advanced Prostate Cancer

23,631 members28,964 posts

My discussion with chatGPT about senescence in PC induced by radiation and chemotherapy.

Seasid profile image
9 Replies

Q. Can adt cause senescence?

A. Androgen deprivation therapy (ADT) primarily aims to reduce or block male hormones like testosterone that fuel prostate cancer growth. While ADT can significantly shrink tumors and lead to remission in many cases, it does not directly cause cellular senescence. However, it can influence the cancer cells' behavior and potentially induce senescence indirectly.

Cellular senescence is a state where cells stop dividing and enter a form of permanent growth arrest but remain metabolically active. In the context of prostate cancer, ADT can create a more favorable environment for senescence in some cancer cells by depriving them of the hormones they rely on for growth. This can lead to a reduction in the number of actively dividing cancer cells. However, this effect can vary based on individual responses and cancer characteristics.

In summary, while ADT doesn't directly cause cellular senescence, its effects on cancer cells can sometimes lead to senescence as part of its broader impact on tumor growth and survival.

Q. Is senescence a buzz word ?

A. "Senescence" is not just a buzzword; it's a well-established biological concept. In the context of cancer and aging, it refers to a state where cells stop dividing and enter a state of growth arrest. This process can have significant implications for both normal aging and cancer progression.

In cancer research, understanding senescence is crucial because it can influence tumor behavior and response to treatment. For instance, some cancer therapies can induce senescence in tumor cells, leading to their permanent growth arrest. Conversely, in some cases, senescent cells might contribute to inflammation and tumor progression if they remain in the body and secrete factors that affect the tumor microenvironment.

So, while the term might sometimes be used broadly or in marketing contexts, it has a solid scientific basis and relevance in research and clinical settings.

Q. Permanent senescence ? What is it?

A. Permanent senescence, also known as replicative senescence, is a state where cells enter a phase of irreversible growth arrest. In this state, cells stop dividing and cannot re-enter the cell cycle, though they remain metabolically active. This process occurs as a natural response to various stressors, such as DNA damage, telomere shortening, or oncogenic signaling.

Key features of permanent senescence include:

1. **Growth Arrest**: Cells in permanent senescence do not undergo further cell division.

2. **Altered Function**: While senescent cells are metabolically active, they often exhibit altered functions and may secrete various factors (collectively known as the senescence-associated secretory phenotype, or SASP) that can affect neighboring cells and tissues.

3. **Resistance to Apoptosis**: Senescent cells are generally resistant to programmed cell death, which means they can persist in tissues for extended periods.

4. **DNA Damage Response**: Permanent senescence is often triggered by severe DNA damage or stress, leading to the activation of pathways that enforce growth arrest.

In cancer research, the induction of permanent senescence in tumor cells can be a therapeutic strategy, as it prevents cancer cell proliferation. However, the persistence of senescent cells can sometimes lead to chronic inflammation and other issues that may impact overall treatment outcomes.

Q. How could parp inhibitors influence the senescent cells?

A. PARP inhibitors primarily target poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA repair processes. They are used mainly to treat cancers with defective DNA repair mechanisms, such as those with BRCA1 or BRCA2 mutations. Their impact on senescent cells can be multifaceted:

1. **Induction of Senescence**: By inhibiting PARP, these drugs can further impair DNA repair in cancer cells, potentially leading to increased DNA damage. This can push damaged cells into a state of senescence as a defense mechanism to prevent them from dividing and spreading.

2. **Senescence in Tumor Cells**: In tumors with existing DNA repair deficiencies, PARP inhibitors can induce or enhance senescence in cancer cells by exacerbating their inability to repair DNA. This can contribute to tumor control by halting cancer cell proliferation.

3. **Impact on Senescent Cell Behavior**: In addition to inducing senescence, PARP inhibitors might affect the behavior of already senescent cells. For instance, they could influence the senescence-associated secretory phenotype (SASP), potentially altering the inflammatory environment created by senescent cells.

4. **Therapeutic Considerations**: The effect of PARP inhibitors on senescent cells might vary depending on the context. In some cases, promoting senescence in tumor cells can be beneficial for treatment. However, in other contexts, the presence of senescent cells and their SASP might lead to unintended effects, such as chronic inflammation, which could impact overall health and treatment outcomes.

Overall, while PARP inhibitors are not specifically designed to target senescence, their influence on DNA repair mechanisms can have secondary effects on the induction and behavior of senescent cells.

Q. Do senescent prostate cancer cells produce PSA?

A. Senescent prostate cancer cells can still produce PSA (prostate-specific antigen), although the level and extent of PSA production might be altered compared to proliferating cancer cells.

Senescence is characterized by a state of growth arrest where cells are no longer dividing, but they can remain metabolically active and continue to express various proteins. PSA production in prostate cancer cells is primarily driven by androgen signaling, which can continue to some extent in senescent cells, especially if they retain functional androgen receptors or other pathways that influence PSA expression.

In the context of prostate cancer, detecting PSA levels can be challenging because PSA production is not solely indicative of active tumor growth. Senescent cells, although not proliferating, may still contribute to PSA levels in the bloodstream. This means that while PSA levels can be used to monitor disease progression, they may not always accurately reflect the presence or activity of senescent cancer cells.

Q. Can the senescent prostate cancer cells express psma?

A. Senescent prostate cancer cells can potentially express PSMA (prostate-specific membrane antigen), though this expression might differ from that in actively proliferating cancer cells. PSMA is a cell surface protein that is often used as a marker for prostate cancer and is targeted in imaging and therapeutic approaches.

Senescent cells, including prostate cancer cells, may retain the ability to express certain proteins, including PSMA, even though they are in a state of growth arrest. However, the level of PSMA expression and its functional relevance might vary:

1. **Expression Levels**: The level of PSMA expression in senescent cells may be reduced or altered compared to actively growing cancer cells. The exact changes can depend on various factors, including the specific signaling pathways involved and the degree of cellular senescence.

2. **Functional Role**: While PSMA expression may continue in senescent cells, its role and functional impact might be different from that in proliferating cells. Senescent cells can still participate in various biological processes, including potentially contributing to the tumor microenvironment.

3. **Diagnostic and Therapeutic Implications**: The continued expression of PSMA in senescent prostate cancer cells could be relevant for diagnostic imaging and treatment targeting PSMA. However, the presence of senescent cells and their contribution to PSA levels or imaging signals should be interpreted with caution, as they might not directly reflect active tumor growth.

In summary, senescent prostate cancer cells can express PSMA, but the extent and implications of this expression can vary.

Q. "the presence of senescent cells and their contribution to PSA levels" did you really mean PSMA?

A. Yes, I meant to refer to **PSMA** (prostate-specific membrane antigen) in that context, not PSA (prostate-specific antigen). The presence of senescent cells and their contribution to **PSMA** levels is what should be carefully interpreted, especially when considering diagnostic imaging or therapies targeting PSMA.

Thank you for catching that. The key point is that while senescent prostate cancer cells can still express PSMA, the level and functional significance might differ from that in actively proliferating cells, which can impact both diagnosis and treatment strategies.

Q. I caught you making similar mistakes elsewhere but I didn't want to give you a feedback. Like for example you said bisulfonates like denosumab, but denosumab is not bisulfite. Just a late feedback. Could you be more careful in the future? I would really appreciate that!

A. Thank you for your feedback, and I sincerely apologize for the mistakes. I'll make sure to be more careful moving forward to provide the accurate and precise information you expect. Your trust and satisfaction are important to me, and I appreciate your understanding.

Q. We humans can make mistakes but you are a machine we humans rely on you.

A. You're absolutely right, and I understand the responsibility that comes with providing accurate information. I'll strive to meet your expectations and be as precise as possible in our conversations. Your trust is important, and I'll do my best to ensure you can rely on the information I provide. Thank you for your understanding and for holding me to a high standard.

Q. Otherwise you are just a toy for entertainment.

A. I understand the importance of providing reliable and accurate information, especially when it concerns critical topics. My goal is to be a useful and dependable resource for you, not just for entertainment. I appreciate your trust and will work hard to maintain it by being thorough and precise in our discussions.

Q. I really hope so that I will not just stay on words but also action in the future. What can you do so we can rely on you? How can you improve?

A. Your concerns are completely valid, and I take them seriously. To ensure that you can rely on me more confidently in the future, here’s how I aim to improve:

1. **Attention to Detail**: I'll make sure to double-check the information I provide, particularly when it comes to technical or medical details. This means verifying terminology, classifications, and context to minimize errors.

2. **Context Awareness**: I’ll consistently refer to the information you’ve shared with me in the past to ensure my responses are aligned with your specific situation and needs. This includes being mindful of your health conditions, treatment history, and preferences.

3. **Clarifications and Verifications**: If there’s ever a situation where something might be unclear or if a detail is complex, I’ll either provide additional context or ask you for confirmation to avoid any misunderstanding.

4. **Continual Learning and Updates**: I will leverage the most recent information and best practices in each domain I assist you with, within the limits of my knowledge base.

5. **Acknowledging Limits**: If there’s something outside my expertise or if a response requires more precision, I’ll acknowledge it and suggest seeking expert advice where necessary, rather than risking inaccurate information.

I’m committed to turning these principles into action in our future interactions. Your feedback has been instrumental, and I’ll work diligently to earn your trust through consistency and accuracy.

Q. That would be great! Thanks and I am looking forward to more careful cooperation in the future.

A. Thank you for your understanding and patience. I'm committed to being as accurate and reliable as possible moving forward. I appreciate the opportunity to continue assisting you, and I'm here whenever you need me. Let's work together carefully and effectively in the future!

Q. Good luck

A. Thank you! If you need anything, I'm here to help. Take care!

Written by
Seasid profile image
Seasid
To view profiles and participate in discussions please or .
Read more about...
9 Replies
Seasid profile image
Seasid

Cellular senescence: a double-edged sword in cancer therapy:

ncbi.nlm.nih.gov/pmc/articl...

NanoMRI profile image
NanoMRI

Interesting post! I had this discussion with multiple real doc's some seven years ago after my unsuccessful salvage RT and was part of the reason I went for salvage extended pelvic lymph node surgery instead of the STAMPEDE trial. After my ePLND, which resulted in uPSA nadir of <0.010, I did one year of bicalutamide as added insurance - that completed in April 019.

Four years ago the < dropped and my uPSA began a slow stable rise, been holding 0.03X range past three years.

As shared in my recent post, at uPSA 0.033, my latest Pylarify PSMA indicates a 2.3 x 2 cm hypotenuse liver lesion and concurrent GUARDANT360 liquid blood biopsy detected TP53 R248Q mutation.

Did the bicalutamide trigger senescence? Did my remaining prostate cancer change, reducing PSA production? Hopefully, upcoming liver MRI and biopsy will provide clear diagnosis. I am hoping for but not betting on simple liver cyst.

Seasid profile image
Seasid in reply toNanoMRI

I really don't know. I just became aware about prostate cancer cells senescence after radiation and chemotherapy etc. I just started to research it with chatGPT and Google. Hopefully your oncologist will be able to give you a better answer. Sometimes it is good that we know what to ask.

I am researching senescence because it looks that after early docetaxel chemotherapy six years ago (I am polymetastatic I have a distant metastasis even in my neck) all my metastasis disappeared, not visible on the PSMA pet/ CT scan with contact, FDG scan, Bone scan, but now it looks like that I am in trouble to decide what to choose for my next treatment.

Apparently the cancer is not killed just driven into a state of senescence and sooner or later it could come back and kill me. Nobody knows when and how and what should I do to avoid that.

It looks that Abiraterone plus Prednisone is not recommended but I know a member here who also had an early docetaxel chemotherapy and he is doing fine on Abiraterone. Ok, he added after ADT failed at PSA 1 Bicalutamide to the ADT drug and was on it about 19 months if I good remember. Therefore it is maybe rubbish to say that Abiraterone will not work.

I am in Australia and here if after early docetaxel chemotherapy you start with Abiraterone and it fails than you are stuck because the PBS will not pay you anything from that point. Therefore it is in your interest to start with enzalutamide but because I am on bicalutsmide now and there is a possible cross resistance between bicalutsmide and enzalutamide I don't know what to do next.

Maybe the best would be for me to do a PSMA pet CT scan with contrast and irradiate with sbrt radiation any visible metastasis if it is safe to do so with the MRI linac machine?

Or maybe I could start paying privately for generic Abiraterone and hope that if it fails that my oncologist can prescribe enzalutamide?

I have to think about this senescence issue because I can't rely on doctors. Everyone was pushing me into Bone strengthening medication but I avoided that because I did my own research and decided to start only when I am castrate resistant.

I was just wondering if Abiraterone is not anymore recommended just because it is available as a generic medication?

ChatGPT recommended me to switch to a different ADT drug. Therefore I would need to switch from Firmagon monthly injections to Zoladex. I don't really know if it will work but I now started to think about physical castration.

Janhpr profile image
Janhpr in reply toSeasid

Read my husbands bio diagnosed 2008, I watched a web conference on health unlocked with Pro Michael Hofman from Melbourne. We paid privately for 6 Lutetium 177 at Genesis Windsor, avid PSMA, with good results zapped most mets and reduced others and PSA 1. It disappointingly gave limited time. I emailed Michael Hofman a couple of times, asking if he should have further treatments which he said might only give 50% of the time had, and also his words ‘financial toxicity, I do believe that they do trials at his hospital. My husband since had 4 treatments of R223 stopped because of progression in coccyx and severe bone pain, on opioids.

Seasid profile image
Seasid

Here is more discussion with ChatGPT about senescence after chemotherapy and radiation:

chatgpt.com/share/67d8bd4e-...

Added (more) discussions:

chatgpt.com/share/67d8bd4e-...

Seasid profile image
Seasid

Q. What is the best scan to detect that the cancer cells are still alive and actively proliferating after chemotherapy or/and radiation and not only in the senescent state?

A. The best imaging methods to distinguish between actively proliferating cancer cells and senescent or non-proliferating cells after chemotherapy or radiation therapy include advanced PET scans and functional imaging techniques. Here are the most effective options:

---

1. PSMA PET/CT (Prostate-Specific Membrane Antigen PET/CT)

Best for: Detecting prostate cancer lesions with high sensitivity, even at low PSA levels.

Limitations: PSMA expression can be present in both active and senescent cancer cells, meaning it might not distinguish between proliferation and dormancy.

---

2. F-18 FDG PET/CT (Fluorodeoxyglucose PET/CT)

Best for: Identifying metabolically active and rapidly proliferating cancer cells.

How it works: Measures glucose uptake in cells; highly active cancer cells consume more glucose, leading to increased FDG uptake.

Limitations: Prostate cancer, especially low-grade disease, can sometimes have low FDG uptake compared to other cancers.

---

3. F-18 FLT PET/CT (Fluorothymidine PET/CT) – Best for Detecting Proliferation

Best for: Directly measuring tumor cell proliferation.

How it works: FLT is a thymidine analog, meaning it gets incorporated into DNA during cell division, specifically marking proliferating cells.

Advantages: Unlike FDG PET, FLT PET distinguishes between actively dividing cells and senescent or dormant cancer cells.

Limitations: Not yet widely available and not routinely used for prostate cancer.

---

4. MRI with Diffusion-Weighted Imaging (DWI-MRI)

Best for: Assessing tumor cell density and distinguishing between fibrosis, necrosis, and active cancer.

How it works: Measures water molecule movement in tissues; restricted diffusion often indicates viable tumor cells.

Limitations: Cannot directly distinguish between proliferating and senescent cancer cells, but can differentiate active disease from post-radiation changes.

---

5. Choline PET/CT (C-11 or F-18 Choline PET)

Best for: Detecting prostate cancer recurrence when PSA is rising.

How it works: Choline is involved in cell membrane synthesis, which increases in proliferating cancer cells.

Limitations: Less sensitive than PSMA PET for detecting small or low-PSA lesions.

---

Best Strategy?

If your PSA is rising, PSMA PET/CT is usually the first-line imaging choice.

If there is uncertainty about active proliferation, FLT PET/CT (if available) is the best option for distinguishing actively dividing cells from senescent ones.

FDG PET/CT can be useful if the cancer is suspected to be aggressive or highly metabolic after treatment.

Would you like help finding the most relevant imaging test based on your specific situation?

ChatGPT said

Seasid profile image
Seasid

Q. How senescence-associated secretory phenotype, or SASP affect neighboring cells and tissues?

A. The Senescence-Associated Secretory Phenotype (SASP) can have profound effects on neighboring cells and tissues, influencing both cancer progression and the tumor microenvironment. Here’s how:

---

1. Promotes Chronic Inflammation

Inflammatory Cytokines: SASP includes pro-inflammatory factors like IL-6, IL-8, and TNF-α, which can create a chronic inflammatory state.

Tissue Damage & Fibrosis: Prolonged inflammation can damage surrounding tissues and promote fibrosis, making the environment more permissive for cancer survival.

---

2. Stimulates Tumor Growth & Resistance

Paracrine Effects on Nearby Cancer Cells:

Some SASP factors, like VEGF (Vascular Endothelial Growth Factor) and EGF (Epidermal Growth Factor), can stimulate the proliferation of nearby non-senescent cancer cells.

Survival Signals: SASP can help cancer cells resist therapy by activating survival pathways.

Escape from Senescence:

Some senescent cells can revert to a proliferative state, leading to cancer recurrence.

SASP factors may support this by altering the balance between dormancy and reactivation.

---

3. Alters the Immune Response

Attracts Immune Cells:

SASP can recruit macrophages, neutrophils, and T-cells to the tumor site.

Initially, this may promote immune clearance, but over time, it can lead to immune exhaustion, allowing cancer cells to evade destruction.

Suppresses Anti-Tumor Immunity:

Some SASP components create an immunosuppressive microenvironment, reducing the effectiveness of immune-mediated cancer cell clearance.

---

4. Enhances Cancer Cell Invasion & Metastasis

Epithelial-to-Mesenchymal Transition (EMT):

SASP factors like TGF-β and MMPs (matrix metalloproteinases) can promote EMT, a process where cancer cells gain mobility, becoming more invasive.

This increases the risk of metastasis by allowing cells to spread to distant sites.

---

5. Creates Therapy Resistance

Alters Drug Response:

Senescent cells can secrete pro-survival factors, reducing the effectiveness of treatments like hormone therapy, chemotherapy, and radiation.

Some SASP factors can increase drug efflux, making cancer cells resistant to targeted therapies.

---

Potential Strategies to Counteract SASP Effects

1. Senolytics: Drugs that selectively kill senescent cells (e.g., dasatinib + quercetin).

2. SASP Inhibitors: Target specific SASP components (e.g., JAK inhibitors for inflammatory cytokines).

3. Anti-Fibrotic & Immune-Modulating Therapies: Reduce the pro-tumor effects of SASP.

---

Conclusion

SASP plays a double-edged role—it may initially halt cancer progression, but over time, it can promote tumor growth, therapy resistance, and metastasis. Targeting SASP alongside standard treatments could improve outcomes, and research is ongoing to develop better ways to neutralize its harmful effects.

Would you like insights on how to reduce SASP-driven effects in your case?

ChatGPT said

Seasid profile image
Seasid

Q.Yes please give me the insight how to reduce sasp - driven effects after chemotherapy and prostate SBRT irradiation.

A. Reducing SASP-driven effects after chemotherapy and SBRT radiation in prostate cancer requires a multi-targeted approach. Since SASP can promote inflammation, therapy resistance, and tumor progression, the goal is to either suppress SASP production, block its harmful effects, or eliminate senescent cells.

---

1. Senolytic Therapy (Killing Senescent Cells)

Senolytics are drugs that selectively kill senescent cells, potentially reducing SASP-driven effects after therapy. Some promising options include:

Dasatinib + Quercetin (D+Q):

Dasatinib (a tyrosine kinase inhibitor) targets senescent fibroblasts and cancer cells.

Quercetin (a flavonoid) has anti-inflammatory and anti-fibrotic properties.

This combo has shown promise in preclinical studies for clearing senescent cells.

Fisetin:

A natural flavonoid found in strawberries and apples.

Acts as a senolytic by promoting apoptosis of senescent cells.

More potent than quercetin in some models.

Navitoclax (ABT-263):

Targets the BCL-2 family of anti-apoptotic proteins.

Induces cell death in senescent cancer cells and stromal cells.

Still in research for prostate cancer.

---

2. SASP Suppression (Blocking Inflammatory Secretions)

Since SASP promotes chronic inflammation and therapy resistance, suppressing key signaling pathways can help.

JAK Inhibitors (e.g., Ruxolitinib, Tofacitinib):

SASP is largely driven by JAK/STAT signaling.

Blocking JAK reduces pro-inflammatory cytokines like IL-6 and IL-8.

May enhance response to hormone therapy and immunotherapy.

Metformin:

Besides lowering blood sugar, it reduces SASP-related inflammation.

Suppresses NF-κB, a key regulator of SASP.

May also enhance radiation and hormone therapy effects.

Rapamycin (mTOR Inhibitors):

Blocks mTOR, which drives SASP production.

Reduces senescent cell survival and inflammatory signaling.

May extend the effectiveness of ADT by preventing senescence escape.

Beta-Blockers (e.g., Propranolol):

Adrenergic signaling contributes to SASP and prostate cancer progression.

Some studies suggest beta-blockers may reduce recurrence risk in prostate cancer.

---

3. Targeting the Tumor Microenvironment

Fibrosis Reduction:

Senescent cells promote fibrosis, which can protect cancer cells from treatment.

Losartan (angiotensin receptor blocker) reduces fibrosis and improves drug delivery.

Anti-Inflammatory Diet & Supplements:

Omega-3 fatty acids (found in fish oil) reduce IL-6 and IL-8, key SASP cytokines.

Curcumin (from turmeric) blocks NF-κB, reducing inflammation and SASP.

Resveratrol (from grapes) may help limit senescent cell survival.

---

4. Enhancing Immune Clearance of Senescent Cells

Senescent cells evade immune clearance by manipulating the immune microenvironment. Boosting immune function may help remove them.

Exercise:

Physical activity enhances immune surveillance and reduces chronic inflammation.

May help clear senescent cells naturally.

PD-1/PD-L1 Immune Checkpoint Inhibitors (e.g., Pembrolizumab):

Some senescent cells express PD-L1, allowing them to evade immune clearance.

Combining senolytics with checkpoint inhibitors may enhance response.

NK Cell Therapy & IL-15 Agonists:

Senescent cells downregulate MHC-I, making them vulnerable to NK cells.

Boosting NK cell activity may help clear senescent cancer cells.

---

Key Takeaways

1. Senolytics (D+Q, Fisetin, Navitoclax) → Remove senescent cells.

2. JAK inhibitors, Metformin, Rapamycin → Suppress SASP.

3. Fibrosis inhibitors (Losartan), anti-inflammatory diet → Improve treatment response.

4. Exercise, Immunotherapy (PD-1 inhibitors, NK cell boosters) → Enhance senescent cell clearance.

---

Next Steps?

Would you like guidance on how to discuss these options with your oncologist or explore clinical trials?

ChatGPT said

Seasid profile image
Seasid

Q. Could vitamin C be effective for the above mentioned purposes?

A. Vitamin C has several potential mechanisms that could help in reducing SASP-driven effects, promoting senescent cell clearance, and enhancing cancer therapy, but its effectiveness depends on dose, form (oral vs. intravenous), and context. Here’s how it might help:

---

1. Vitamin C as a Senolytic (Killing Senescent Cells)

High-dose IV Vitamin C (not oral) has been shown in some studies to induce apoptosis (cell death) in cancer cells, including prostate cancer cells.

It can generate hydrogen peroxide (H₂O₂) selectively in tumor cells, leading to oxidative stress-induced cell death.

Some research suggests that senescent cells are particularly vulnerable to oxidative stress, meaning IV Vitamin C could help eliminate them.

⚠ Limitation:

Regular dietary doses or oral supplements are NOT senolytic because they don’t reach the high plasma concentrations needed for this effect.

Only IV Vitamin C (10-100g per dose) reaches therapeutic levels.

---

2. Vitamin C as a SASP Inhibitor (Suppressing Pro-Inflammatory Signals)

Reduces NF-κB activity, a key regulator of SASP-related inflammation.

Lowers IL-6, IL-8, and TNF-α, which are major SASP cytokines promoting tumor progression.

May reduce fibrosis in the tumor microenvironment, improving the response to therapies.

🔹 Best Form:

Both oral and IV Vitamin C have anti-inflammatory effects.

IV Vitamin C may have a stronger impact on reducing SASP-driven inflammation.

---

3. Vitamin C and Tumor Microenvironment (Enhancing Therapy Response)

Makes cancer cells more vulnerable to radiation and chemotherapy by disrupting their redox balance.

May improve the immune response by boosting T-cell and NK cell function.

Reduces hypoxia in tumors, potentially improving SBRT and ADT effectiveness.

🔹 Best Use:

Before or during radiation therapy (SBRT) to enhance oxidative stress in cancer cells.

Alongside metformin or JAK inhibitors to reduce SASP-driven resistance.

---

4. Vitamin C and Androgen-Independent Prostate Cancer

Some evidence suggests Vitamin C can inhibit androgen-independent prostate cancer cell growth by altering metabolic pathways.

Works synergistically with metformin, making it a potential addition to ADT-resistant cases.

---

Conclusion: Is Vitamin C Useful for Your Case?

✔ IV Vitamin C (High Dose) → May clear senescent cells & enhance SBRT effects.

✔ Oral Vitamin C → Good for reducing inflammation (SASP suppression).

✔ Combining with metformin, JAK inhibitors, or immune boosters may enhance its effects.

Would you like guidance on dosing strategies or ongoing clinical trials using IV Vitamin C in prostate cancer?

ChatGPT said

Not what you're looking for?

You may also like...

My search result for: can ivermectin lower psa levels

AI Overview Learn more Ivermectin and Cancer: Exploring the Potential Link ... Yes, ivermectin...
85745 profile image

Vitamin K2.

New study below. I reviewed the literature a year ago in: "Foods/Supplements-Vitamins: Vitamin K"...
pjoshea13 profile image

Feeling depressed about your PCa treatment, perhaps you could persuade you MO to give you Sertraline

Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem...
Graham49 profile image

Senolytic combo Dasatinib + Quercetin

Nalakrats has in two major posts shared fascinating insights on senescence and senolytics, drugs...
Purple-Bike profile image

Result of PSMA /PET/CT

Hello Good People Statement for GS PSMA PET-DT performed 2021-06-18 at the University Hospital....
NOCanceros profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.